Drug Trial Radar · NCT06122662
AMX0035 and Progressive Supranuclear Palsy
Last checked: Nov 19, 2026Latest source record: Apr 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
139
Actual
Start
Dec 21, 2023
Primary completion
Sep 30, 2025
Study completion Oct 21, 2025
Sponsor
- Lead sponsor
- Amylyx Pharmaceuticals Inc.Industry
- Sponsor type
- Industry
- First posted
- Nov 8, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 40 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A35-009 (ORION) is a Phase 2b/3 trial to evaluate the efficacy and safety of AMX0035 in participants with Progressive Supranuclear Palsy (PSP), consisting of randomized, double blind placebo controlled phases, followed by an optional open-label extension phase.
Conditions
- Progressive Supranuclear Palsy
- PSP
- Neurodegenerative Diseases
- Atypical Parkinsonism
Interventions
AMX0035Drug
Proprietary formulation of sodium phenylbutyrate and taurursodiol
PlaceboOther
Matching Placebo Comparator
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in total (28-item) Progressive Supranuclear Palsy Rating Scale (PSPRS) ScoreTime frame: 52 weeks
Locations
62 sites in 5 countries. Site status is shown where the registry gives one.
Mayo Clinic
Scottsdale, Arizona
University of Arkansas for Medical Sciences
Little Rock, Arkansas
Parkinson's & Movement Disorder Institute
Fountain Valley, California
University of Southern California
Los Angeles, California
Cedars Sinai Medical Center
Los Angeles, California
Stanford Movement Disorder Center
Palo Alto, California
University of California, San Francisco (UCSF)
San Francisco, California
UC Health Anschutz Outpatient Pavilion Anschutz Medical Campus
Aurora, Colorado
Parkinson's Disease and Movement Disorders Center of Boca Raton
Boca Raton, Florida
UF Health Dorothy Mangurian Neuroimaging Suite
Gainesville, Florida
Mayo Clinic Florida
Jacksonville, Florida
Augusta University
Augusta, Georgia
Parkinsons and Movement Disorder Center at the Queens Medical Center
Honolulu, Hawaii
Northwestern University PD and Movement Disorders Center
Chicago, Illinois
University of Kansas Medical Center Research Institute, Inc.
Kansas City, Kansas
University of Kentucky Medical Center
Lexington, Kentucky
Ochsner Medical Center
New Orleans, Louisiana
Massachusetts General Hospital
Boston, Massachusetts
Lahey Hospital and Medical Center
Burlington, Massachusetts
Quest Research Institute
Farmington Hills, Michigan
University of Minnesota, CTSI
Minneapolis, Minnesota
Mayo Clinic - Rochester
Rochester, Missouri
Cleveland Clinic Lou Ruvo Center for Brain Health
Las Vegas, Nevada
University of Cincinnati
Cincinnati, Ohio
The Cleveland Clinic Foundation
Cleveland, Ohio
Oregon Health & Science University
Portland, Oregon
Pennsylvania Hospital
Philadelphia, Pennsylvania
Medical University of South Carolina (MUSC)
Charleston, South Carolina
Veracity Neuroscience, LLC
Memphis, Tennessee
Vanderbilt University Medical Center
Nashville, Tennessee
Kerwin Medical Center
Dallas, Texas
Baylor College of Medicine
Houston, Texas
Central Texas Neurology Consultants
Round Rock, Texas
University of Utah Movement Disorders Center
Salt Lake City, Utah
Virginia Commonwealth University Department of Neurology
Richmond, Virginia
Groupe Hospitalier Pitie-Salpetriere
Paris, France
Hôpital de la Timone
Marseille, Bouches-du-Rhône, France
Hopital Caremeau
Nîmes, Gard, France
Groupe Hospitalier Pellegrin - Hôpital Pellegrin
Bordeaux, Gironde, France
CHU de Limoges - Hôpital Dupuytren
Limoges, Haute Vienne, France
Showing 40 of 62 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.